Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2022-12-02 00:00:00 ET · period of report 2022-12-01 · accession 0001127602-22-026832 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-02 | 2022-12-01+ | BCRX | Stonehouse Jon P | Pres, CEO, Dir | S - Sale+OE | $12.94 | -297.6K | 901.8K | -25% | -$3.85M |
| DM | 2022-12-02 | 2022-12-01+ | BCRX | Stonehouse Jon P | Pres, CEO, Dir | M - OptEx | $1.42 | +297.6K | 1.12M | +36% | +$422.6K |
| DM | 2022-12-02 | 2022-12-01+ | BCRX | Stonehouse Jon P | Pres, CEO, Dir | M - OptEx | $0.00 | -297.6K | 82.7K | -78% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-02 | S | D | 82,656 | $12.80 | 901,830 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2022-12-02 | M | A | 82,656 | $1.42 | 984,486 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. |
| 3 | Common | Common Stock | 2022-12-01 | M | A | 214,917 | $1.42 | 1,116,747 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. |
| 4 | Common | Common Stock | 2022-12-01 | S | D | 214,917 | $13.00 | 901,830 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. (F2) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.75 to $13.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| 5 | Derivative | Emp. Stock Option (Right to Buy) | 2022-12-02 | M | D | 82,656 | $0.00 | 0 | D | $1.42 · 2014-01-01 to 2023-01-01 | 82,656 Common Stock | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. |
| 6 | Derivative | Emp. Stock Option (Right to Buy) | 2022-12-01 | M | D | 214,917 | $0.00 | 82,656 | D | $1.42 · 2014-01-01 to 2023-01-01 | 214,917 Common Stock | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. |